<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02057679</url>
  </required_header>
  <id_info>
    <org_study_id>2111</org_study_id>
    <nct_id>NCT02057679</nct_id>
  </id_info>
  <brief_title>Extended Antibiotic Therapy in Postoperative of Laparoscopic Cholecystectomy in Acute Cholecystitis</brief_title>
  <official_title>Extended Antibiotic Therapy in Postoperative of Laparoscopic Cholecystectomy Due to Acute Cholecystitis. Is it Necessary?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Italiano de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Italiano de Buenos Aires</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute cholecystitis (AC) is a very common complication of cholelithiasis, encountered in 20%
      of symptomatic patients.

      Nowadays laparoscopic cholecystectomy (LC) is the standard treatment in mild and moderates
      forms of diseases and antibiotic therapy in the postoperatory of these patients remains under
      discussion. However in the beginning, AC presents itself as an steril process, the
      obstruction of the cystic duct initiates a cascade of inflammation, ischaemia and necrosis,
      as well as bacterial proliferation within the gallbladder lumen. Bactibilia was a significant
      factor associated with total, as well as infectious, operative complications. Regarding this,
      for some authors, monotherapy with amoxicillin clavulanic (AMC) would be the best treatment
      after LC in patients with mild and moderate cholecystitis without intraoperative
      complications such as bile peritonitis, cholangitis, gallbladder perforation or abscess. In
      the other hand, others do not prescribe antimicrobial treatment after surgery in these
      selected patients.

      There is controversy regarding the postoperative treatment with antibiotics in patients with
      mild and moderate cholecystitis and all the evidence about this topic.

      Therefore, investigators decided to conduct a prospective randomized study in patients
      undergoing laparoscopic cholecystectomy for acute mild and moderate cholecystitis cancer. The
      patients will be randomized to receive AMC or placebo after surgery. With this study
      investigators intend to prove that are no clinical differences in postoperative outcomes
      between patients treated with AMC and placebo.

      The primary aim of the trial is to assess that there are no benefits in the use of
      postoperative antibiotics in patients whit mild or moderate acute cholecystitis in whom a
      laparoscopic cholecystectomy was performed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind randomized clinical trial
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of infectious postoperative complications</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of infectious postoperative complications in patients who underwent a laparoscopic cholecystectomy due to acute mild and moderate cholecystitis, with antibiotics or placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of days of hospital stay or readmissions.</measure>
    <time_frame>30 days</time_frame>
    <description>To evaluate hospital stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of surgical reinterventions or reoperations.</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Cholecystitis</condition>
  <arm_group>
    <arm_group_label>Group A (Amoxicillin Clavulanic)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intake of active drug (Amoxicillin Clavulanic). 3 g per day divided into 3 oral intakes of 1 g each (2 pill of Amoxicillin Clavulanic every 8 hrs). This treatment will begin on postoperative day 1 for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intake of placebo (Lactose). 1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin clavulanic</intervention_name>
    <description>3 g per day divided into 3 oral intakes of 1 g each (2 pill of Amoxicillin Clavulanic every 8 hrs). This treatment will begin on postoperative day 1 for 5 days.</description>
    <arm_group_label>Group A (Amoxicillin Clavulanic)</arm_group_label>
    <other_name>Optamox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Lactose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 85 years old

          -  Patients with diagnose of mild or moderate acute cholecystitis.

          -  Underwent laparoscopic cholecystectomy on Italian Hospital of Buenos Aires

        Exclusion Criteria:

          -  They refuse to participate from the trial or the process of informed consent.

          -  Have known allergies or hypersensitivity to Mosapride or lactose (used for placebo).

          -  Patients with severe cholecystitis

          -  Patients with moderate cholecystitis who presents liver abscess, gallbladder abscess,
             cholangitis or bile peritonitis.

          -  Intraoperative findings like liver cancer, liver metastases, common bile duct stones
             or gallbladder carcinoma.

          -  Patients with conversion to laparotomy

          -  Previous treatment with antibiotics for more than five days.

          -  Patients with active oncological diseases, AIDS, diabetes, transplanted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin de Santiba√±es, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Italiano de Buenos Aires</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diego Giunta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Italiano de Buenos Aires</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pablo A. Pellegrini, MD</last_name>
    <phone>0054-011 1559679722</phone>
    <email>pablo.pellegrini@hospitalitaliano.org.ar</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>1199</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo A. Pellegrini, MD</last_name>
      <phone>54 11 59679722</phone>
      <email>pablo.pellegrini@hospitalitaliano.org.ar</email>
    </contact>
    <investigator>
      <last_name>Pablo A. Pellegrini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agustin DIetrich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oscar M. Mazza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Barcan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <reference>
    <citation>Strasberg SM. Clinical practice. Acute calculous cholecystitis. N Engl J Med. 2008 Jun 26;358(26):2804-11. doi: 10.1056/NEJMcp0800929. Review. Erratum in: N Engl J Med. 2008 Jul 17;359(3):325.</citation>
    <PMID>18579815</PMID>
  </reference>
  <reference>
    <citation>Yoshida M, Takada T, Kawarada Y, Tanaka A, Nimura Y, Gomi H, Hirota M, Miura F, Wada K, Mayumi T, Solomkin JS, Strasberg S, Pitt HA, Belghiti J, de Santibanes E, Fan ST, Chen MF, Belli G, Hilvano SC, Kim SW, Ker CG. Antimicrobial therapy for acute cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg. 2007;14(1):83-90. Epub 2007 Jan 30.</citation>
    <PMID>17252301</PMID>
  </reference>
  <reference>
    <citation>Yildiz B, Abbasoglu O, Tirnaksiz B, Hamaloglu E, Ozdemir A, Sayek I. Determinants of postoperative infection after laparoscopic cholecystectomy. Hepatogastroenterology. 2009 May-Jun;56(91-92):589-92.</citation>
    <PMID>19621660</PMID>
  </reference>
  <reference>
    <citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.</citation>
    <PMID>3558716</PMID>
  </reference>
  <reference>
    <citation>Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santiba√±es E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009 Aug;250(2):187-96. doi: 10.1097/SLA.0b013e3181b13ca2.</citation>
    <PMID>19638912</PMID>
  </reference>
  <reference>
    <citation>Yokoe M, Takada T, Strasberg SM, Solomkin JS, Mayumi T, Gomi H, Pitt HA, Gouma DJ, Garden OJ, B√ºchler MW, Kiriyama S, Kimura Y, Tsuyuguchi T, Itoi T, Yoshida M, Miura F, Yamashita Y, Okamoto K, Gabata T, Hata J, Higuchi R, Windsor JA, Bornman PC, Fan ST, Singh H, de Santibanes E, Kusachi S, Murata A, Chen XP, Jagannath P, Lee S, Padbury R, Chen MF; Tokyo Guidelines Revision Committee. New diagnostic criteria and severity assessment of acute cholecystitis in revised Tokyo Guidelines. J Hepatobiliary Pancreat Sci. 2012 Sep;19(5):578-85. doi: 10.1007/s00534-012-0548-0.</citation>
    <PMID>22872303</PMID>
  </reference>
  <reference>
    <citation>Kanafani ZA, Khalif√© N, Kanj SS, Araj GF, Khalifeh M, Sharara AI. Antibiotic use in acute cholecystitis: practice patterns in the absence of evidence-based guidelines. J Infect. 2005 Aug;51(2):128-34. Epub 2005 Jan 20. Review.</citation>
    <PMID>16038763</PMID>
  </reference>
  <reference>
    <citation>Grande M, Torquati A, Farinon AM. Wound infection after cholecystectomy. Correlation between bacteria in bile and wound infection after operation on the gallbladder for acute and chronic gallstone disease. Eur J Surg. 1992 Feb;158(2):109-12.</citation>
    <PMID>1350211</PMID>
  </reference>
  <reference>
    <citation>Galili O, Eldar S Jr, Matter I, Madi H, Brodsky A, Galis I, Eldar S Sr. The effect of bactibilia on the course and outcome of laparoscopic cholecystectomy. Eur J Clin Microbiol Infect Dis. 2008 Sep;27(9):797-803. doi: 10.1007/s10096-008-0504-8. Epub 2008 Mar 28.</citation>
    <PMID>18369670</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2014</study_first_submitted>
  <study_first_submitted_qc>February 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2014</study_first_posted>
  <last_update_submitted>December 16, 2015</last_update_submitted>
  <last_update_submitted_qc>December 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Italiano de Buenos Aires</investigator_affiliation>
    <investigator_full_name>Diego Hernan Giunta, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Acute cholecystitis.</keyword>
  <keyword>Amoxicillin clavulanic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecystitis</mesh_term>
    <mesh_term>Acalculous Cholecystitis</mesh_term>
    <mesh_term>Cholecystitis, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

